Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Asandeutertinib vs Osimertinib in EGFR-mutated NSCLC
NCT05382728Phase 3Recruiting
- Sponsor
- TYK Medicines
- Start
- Jun 2022
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of asandeutertinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by TYK Medicines. Primary endpoint: Progression-Free Survival. Started Jun 2022; status: recruiting.
02
Drugs
asandeutertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05382728.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05382728.